| Literature DB >> 31143772 |
Wafa Rhimi1,2, Raoudha Hlel1,2, Issam Ben Salem2, Abdennacer Boulila3, Ahmed Rejeb4, Mouldi Saidi2.
Abstract
Dittrichia viscosa which belongs to the Asteraceae family is frequently used to treat hematomas and skin disorders in Mediterranean herbal medicine. This study aims to validate its antioxidant effects and its potential on healing wounds. The ethanolic extract of D. viscosa leaves was formulated as 2.5% and 5% (w/w) in ointment bases on the beeswax and sesame oil. During this study, the ethanolic D. viscosa extract, ointments containing 2.5% and 5% of D. viscosa extract, and the vehiculum were assessed for their total phenol content (TPC), caffeoylquinic acid content (CQC), and antioxidant activities using complementary methods (TAC, the DPPH, ABTS, FRAP, and the BCB). The effects on wound healing of obtained ointments were evaluated by excision of the wound in a mice model for 12 days. Subsequently, the excised wound areas were measured at the 3rd, 9th, and 12th days. The skin tissues were isolated for histological studies. The ointments containing D. viscosa extract (2.5%, 5%) possessed a considerable TPC, CQC, radical scavenging potential, and antioxidant activities compared to the vehiculum. Treated animals with ointments containing D. viscosa extract at 2.5% and 5% showed almost and totally healed wounds compared to the vehiculum and control groups, evidenced by good skin regeneration and reepithelialization. The present work showed the role of D. viscosa antioxidants exerted by its polyphenolic compounds, in particular, caffeoylquinic acids, in enhancing wound healing.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31143772 PMCID: PMC6501256 DOI: 10.1155/2019/4081253
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Retention time, UV and mass spectral data, and tentative identification of the phenolic components in ethanolic leaves extractof D. viscosa.
| Peak n | Tr (min) |
| [M-H]− (m/z) | Fragments ions (m/z) | Tentative of identification | Ref/std |
|---|---|---|---|---|---|---|
| 1 | 7.969 | 325 | 353 | 191 (100)-161(10) | Chlorogenic acid | std |
| 2 | 8.231 | 260-324 | 375 | 375(20)-191(100) | 3-o-Caffeoylquinic acid | std |
| 3 | 9.153 | 293-324- | 543 | 387(50)-191(100) | 1,3-O-Dicaffeoylquinic acid | std |
| 4 | 11.405 | 260 | 599 | 467(100) | Ganoderic acid C6 | [ |
| 5 | 11.694 | 260 | 599 | 467(100) | Ganoderic acid C6 | [ |
| 6 | 12.243 | 280 | 583 | 467(100)-329(50) | Ganoderic acid D | [ |
| 7 | 18.712 | 284sh | 609 | 429(60)-341(20)-301(100)-151(60) | Quercetin-galactosylrhamnoside | [ |
| 8 | 19.609 | 260-284sh | 741 | 509(50)- 301(100)- 241(60) | Rutin-O-pentoside | [ |
| 9 | 20.751 | 260-331 | 463 | 301(100)-179(20)-151(30) | Quercetin-3-O-glucoside | [ |
| 10 | 21.158 | 260-332 | 591 | 301(100)-179(20)-151(30) | Rutin | std |
| 11 | 22.791 | 326 sh | 741 | 301(100)-241(20)-151(30) | Quercetin-7-O-xyloside-3-O-rutinoside | [ |
| 12 | 23.350 | 327 | 515 | 315(70)-191(40)-179(100) | 3,4-Dicaffeoylquinic acid | std |
| 13 | 25.543 | 327 | 515 | 353 (33)-191 (100)- 179(30) | 3,5-Dicaffeoylquinic acid | std |
| 14 | 26.253 | 327 | 677 | 515(15)-353(15)-191(100)-179(40)-135(20) | Dicaffeoylquinic acid glucoside | [ |
| 15 | 27.015 | 326 | 653 | 515(15)-353(15)-191(100)-179(40)-135(20 | 3, 4,5-Tricaffeoylquinic acid | std |
| 16 | 28.901 | 327 | 515 | 353(30)-191(50)-179(100)-135(40) | 1,5-Dicaffeoylquinic acid | std |
| 17 | 29.180 | 327 | 515 | 353(30)-191(50)-179(100)-135(40) | 3,5-Dicaffeoylquinic acid | std |
| 18 | 30.525 | 324 | 591 | 509(30)-191(70)-179(100) | 4,5-Dicaffeoylquinic acid | std |
| 19 | 32.022 | 326 | 790 | 591- 405(80)-241(100)-191(60) | Dehydrodimers of caffeic acid | [ |
| 20 | 33.291 | 260-327 | 489 | 241(100) | Isoorientin | [ |
| 21 | 35.414 | 281-327 | 489 | 241(100) | Isoorientin | [ |
| 22 | 36.108 | 292-323 | 303 | 241(60), 151(100) | Dihydroquercetin | [ |
| 23 | 39.280 | 280-328 | 567 | 413(100) | Apigenin-glucoside | [ |
| 24 | 41.792 | 288 | 493 | 493(100) | Myricetin-O-glucuronide | [ |
| 25 | 44.651 | 332-288 | 495 | 493(100) | Dihydromyricetin-O-glucuronide | [ |
| 26 | 46.004 | 260-297-330 | 493 | 493(75)-315(100)-300 (50)-271 (80) | Isorhamnetin-O-glucuronopyranoside | [ |
| 27 | 47.815 | 260-290-331 | 533 | 515(100), 353 (80) | Dicaffeoylquinic derivatives | std |
| 28 | 51.130 | 260-327 | 757 | 553(25), 323 (20), 203(100), 165 (50), 133 (30) | Caffeoyl-N-tryptophan | [ |
| 29 | 52.061 | 260-330 | 553 | 265(70), 203(100), 163(40) | Caffeoyl-N-tryptophan-rhamnoside | [ |
Total phenol content (TPC), caffeoylquinic acid content (CQC) of D. viscosa ethanolic extract, ointment base, and ointment containing 5% and 2.5% of extract.
| Ethanolic extract [ | Ointment containing 2.5% of extract | Ointment containing 5% of extract | Ointment base (vehiculum) | |
|---|---|---|---|---|
| TPC (mg GAE/g of sample) | 117.58 ± 1.29 | 4.70 ± 0.19 | 11.27 ± 0.121 | 0.94 ± 0.05 |
| CQC (mg ChlA/g of sample) | 71.85 ± 0.35 | 1.85 ± 0.06 | 4.77 ± 0.02 | 0.00±0.00 |
Total antioxidant capacity, free radical scavenging (DPPH; ABTS), ferric reducing power, linoleic acid inhibition of D. viscosa ethanolic extract, ointment base, and ointment containing 5% and 2.5% of extract.
|
|
|
|
| ß- | |
|---|---|---|---|---|---|
| Ethanolic extract | 133.02 ± 3.1 | 56.25 ± 1.2 | 147.26 ± 1.5 | 296.425 ± 3.3 | 54.01± 1.4 |
| (%I for 1 mg/mL) | |||||
| Ointment base (Vehiculum) | 1.61± 0.1 | 7977.00 ± 225.0 | 12550 ± 132 | 4.37 ±0.3 | 10.85 ± 1.1 (%I for 10 mg/mL) |
| Ointment containing 2.5% of extract | 3.41 ±0.2 | 3073.70±138.8 | 6290± 183.9 | 11.69 ± 0.2 | 36.22 ± 0.9 |
| (%I for 10 mg/mL) | |||||
| Ointment containing 5% of extract | 7.46 ± 0.7 | 1360.50±90.6 | 3473.7± 217.5 | 19.85 ± 0.4 | 48.05± 1.8 |
| (%I for 10 mg/mL) | |||||
| BHT | - | 26.92 ± 1.22 | 42.64 ± 0.12 | - | 62.18 ± 1.6 |
| (% I for 1 mg/mL) |
Values expressed are means ± S.D.
Figure 1Percentage of wound contraction rate of mice treated with D. viscosa (2.5%, 5%) ointments, positive control (vehicle) and negative control on in vivo wound model.
Figure 2Morphological representation on wound contraction of different groups after 3, 9, and 12 days of topical application: ∗C3: control day 3; ∗C9: control day 9; ∗C12: control day 12; ∗V3: control day 3; ∗V9: control day 9; ∗V12: control day 12; O (2.5%) a: ointment containing D. viscosa (2.5%) day 3; O (2.5%) b: ointment containing D. viscosa (2.5%) day 9; O (2.5%) a: ointment containing D. viscosa (2.5%) day 12; O (2.5%) a: ointment containing D. viscosa (5%) day 3; O (2.5%) b: ointment containing D. viscosa (5%) day 9; O (2.5%) a: ointment containing D. viscosa (5%) day 12.
Figure 3Histological sections of mice of different groups after 3, 9, and 12 days of topical application C3, V3, O (2.5%) a, and O (5%) a: complete destruction acute of epiderm, presence of inflammatory cells, and fibrin. C9, C12, V9, and V12: acute inflammation and destruction of epiderm. O (2.5%) b: proliferation of collagens fibers, inflammatory discreet infiltrate, and reepithelization. O (5%) b: proliferation of collagens fibers and inflammatory discreet infiltrate more important than those observed in O (2.5%) b. O (2.5%) c: Complete reepithelization. O (5%) c: reepithelization and crosslinking of collagen fibers.